Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Parvifloron D from Plectranthus strigosus: Cytotoxicity Screening of Plectranthus spp. Extracts.

Garcia C, Ntungwe E, Rebelo A, Bessa C, Stankovic T, Dinic J, Díaz-Lanza A, P Reis C, Roberto A, Pereira P, Cebola MJ, Saraiva L, Pesic M, Duarte N, Rijo P.

Biomolecules. 2019 Oct 17;9(10). pii: E616. doi: 10.3390/biom9100616.

2.

Cytotoxic Activity of Royleanone Diterpenes from Plectranthus madagascariensis Benth.

Matias D, Nicolai M, Saraiva L, Pinheiro R, Faustino C, Diaz Lanza A, Pinto Reis C, Stankovic T, Dinic J, Pesic M, Rijo P.

ACS Omega. 2019 May 2;4(5):8094-8103. doi: 10.1021/acsomega.9b00512. eCollection 2019 May 31.

3.

Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.

Podolski-Renić A, Dinić J, Stanković T, Jovanović M, Ramović A, Pustenko A, Žalubovskis R, Pešić M.

Eur J Pharm Sci. 2019 Oct 1;138:105012. doi: 10.1016/j.ejps.2019.105012. Epub 2019 Jul 19.

PMID:
31330259
4.

A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor.

Fallacara AL, Zamperini C, Podolski-Renić A, Dinić J, Stanković T, Stepanović M, Mancini A, Rango E, Iovenitti G, Molinari A, Bugli F, Sanguinetti M, Torelli R, Martini M, Maccari L, Valoti M, Dreassi E, Botta M, Pešić M, Schenone S.

Cancers (Basel). 2019 Jun 19;11(6). pii: E848. doi: 10.3390/cancers11060848.

5.

Computational spectroscopy of trehalose, sucrose, maltose, and glucose: A comprehensive study of TDSS, NQR, NOE, and DRS.

Heid E, Honegger P, Braun D, Szabadi A, Stankovic T, Steinhauser O, Schröder C.

J Chem Phys. 2019 May 7;150(17):175102. doi: 10.1063/1.5095058.

PMID:
31067863
6.

Modulation of Antioxidant Potential with Coenzyme Q10 Suppressed Invasion of Temozolomide-Resistant Rat Glioma In Vitro and In Vivo.

Burić SS, Podolski-Renić A, Dinić J, Stanković T, Jovanović M, Hadžić S, Ayuso JM, Virumbrales-Muñoz M, Fernández LJ, Ochoa I, Pérez-García VM, Pešić M.

Oxid Med Cell Longev. 2019 Mar 12;2019:3061607. doi: 10.1155/2019/3061607. eCollection 2019.

7.

Association of Overexpressed MYC Gene with Altered PHACTR3 and E2F4 Genes Contributes to Non-small Cell Lung Carcinoma Pathogenesis.

Dragoj M, Bankovic J, Podolski-Renic A, Buric SS, Pesic M, Tanic N, Stankovic T.

J Med Biochem. 2019 Mar 3;38(2):188-195. doi: 10.2478/jomb-2018-0022. eCollection 2019 Apr.

8.

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.

Balmus G, Pilger D, Coates J, Demir M, Sczaniecka-Clift M, Barros AC, Woods M, Fu B, Yang F, Chen E, Ostermaier M, Stankovic T, Ponstingl H, Herzog M, Yusa K, Martinez FM, Durant ST, Galanty Y, Beli P, Adams DJ, Bradley A, Metzakopian E, Forment JV, Jackson SP.

Nat Commun. 2019 Jan 8;10(1):87. doi: 10.1038/s41467-018-07729-2.

9.

PALB2 variant status in hematological malignancies - a potential therapeutic target?

Oldreive CE, Byrd PJ, Stewart GS, Taylor AJ, Farhat S, Skowronska A, Smith E, Raghavan M, Janic D, Dokmanovic L, Clokie S, Davies N, Kwok M, Pratt G, Paneesha S, Moss P, Stankovic T, Taylor M.

Leuk Lymphoma. 2019 Jul;60(7):1823-1826. doi: 10.1080/10428194.2018.1551539. Epub 2019 Jan 7. No abstract available.

PMID:
30614742
10.

In silico Analysis Suggests Common Appearance of scaRNAs in Type II Systems and Their Association With Bacterial Virulence.

Guzina J, Chen WH, Stankovic T, Djordjevic M, Zdobnov E, Djordjevic M.

Front Genet. 2018 Oct 17;9:474. doi: 10.3389/fgene.2018.00474. eCollection 2018.

11.

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.

Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D.

Nature. 2018 Jul;559(7713):285-289. doi: 10.1038/s41586-018-0291-z. Epub 2018 Jul 4.

12.

Attaining in vivo selectivity of positive modulation of α3βγ2 GABAA receptors in rats: A hard task!

Batinić B, Stanković T, Stephen MR, Kodali R, Tiruveedhula VV, Li G, Scholze P, Marković BD, Obradović AL, Ernst M, Cook JM, Savić MM.

Eur Neuropsychopharmacol. 2018 Aug;28(8):903-914. doi: 10.1016/j.euroneuro.2018.05.014. Epub 2018 Jun 19.

PMID:
29891214
13.

Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.

Stankovic T, Dinic J, Podolski-Renic A, Musso L, Buric SS, Dallavalle S, Pesic M.

Curr Med Chem. 2018 Jun 6. doi: 10.2174/0929867325666180607094856. [Epub ahead of print]

PMID:
29874992
14.

Anticancer properties of the abietane diterpene 6,7-dehydroroyleanone obtained by optimized extraction.

Garcia C, Silva CO, Monteiro CM, Nicolai M, Viana A, Andrade JM, Barasoain I, Stankovic T, Quintana J, Hernández I, González I, Estévez F, Díaz-Lanza AM, Reis CP, Afonso CA, Pesic M, Rijo P.

Future Med Chem. 2018 May 1;10(10):1177-1189. doi: 10.4155/fmc-2017-0239. Epub 2018 May 11.

PMID:
29749759
15.

Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.

Weston VJ, Wei W, Stankovic T, Kearns P.

Exp Hematol. 2018 Jul;63:52-63.e5. doi: 10.1016/j.exphem.2018.04.002. Epub 2018 Apr 12.

16.

Quality of life in patients with MuSK positive myasthenia gravis.

Stankovic M, Peric S, Stojiljkovic Tamas O, Stankovic T, Nikolic A, Lavrnic D, Basta I.

Acta Neurol Belg. 2018 Sep;118(3):423-427. doi: 10.1007/s13760-018-0915-y. Epub 2018 Mar 28.

PMID:
29594965
17.

Jatrophane diterpenoids with multidrug-resistance modulating activity from the latex of Euphorbia nicaeensis.

Krstić G, Jadranin M, Todorović NM, Pešić M, Stanković T, Aljančić IS, Tešević VV.

Phytochemistry. 2018 Apr;148:104-112. doi: 10.1016/j.phytochem.2018.01.016. Epub 2018 Feb 6.

PMID:
29421506
18.

Clinical manifestations in trisomy 9 mosaicism.

Pejcic L, Stankovic T, Ratkovic-Jankovic M, Vasic K, Nikolic I.

Turk J Pediatr. 2018;60(6):729-734. doi: 10.24953/turkjped.2018.06.015.

19.

Using verbal instructions to influence lifting mechanics - Does the directive "lift with your legs, not your back" attenuate spinal flexion?

Beach TAC, Stankovic T, Carnegie DR, Micay R, Frost DM.

J Electromyogr Kinesiol. 2018 Feb;38:1-6. doi: 10.1016/j.jelekin.2017.10.008. Epub 2017 Oct 31.

PMID:
29107836
20.

Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Dragoj M, Bankovic J, Sereti E, Stojanov SJ, Dimas K, Pesic M, Stankovic T.

Invest New Drugs. 2017 Dec;35(6):718-732. doi: 10.1007/s10637-017-0494-4. Epub 2017 Jul 22.

PMID:
28733702
21.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T.

Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23. No abstract available.

PMID:
28643365
22.

Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.

Davies NJ, Kwok M, Gould C, Oldreive CE, Mao J, Parry H, Smith E, Agathanggelou A, Pratt G, Taylor AMR, Moss P, Griffiths M, Stankovic T.

Oncotarget. 2017 Jul 4;8(27):44749-44760. doi: 10.18632/oncotarget.17432.

23.

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, Mao J, Da Costa D, Yadollahi S, Perry T, Kearns P, Skowronska A, Yates E, Parry H, Hillmen P, Reverdy C, Delansorne R, Paneesha S, Pratt G, Moss P, Taylor AMR, Stewart GS, Stankovic T.

Blood. 2017 Jul 13;130(2):156-166. doi: 10.1182/blood-2016-12-758219. Epub 2017 May 11.

PMID:
28495793
24.

Interleukin 6 as a potential diagnostic and prognostic biomarker in saliva in patients with carcinoma of the larynx.

Milisavljevic D, Krstic M, Stankovic T.

Hippokratia. 2016 Apr-Jun;20(2):174. No abstract available.

25.

Contribution of bacterial promoter elements to transcription start site detection accuracy.

Nikolic M, Stankovic T, Djordjevic M.

J Bioinform Comput Biol. 2017 Apr;15(2):1650038. doi: 10.1142/S0219720016500384. Epub 2016 Nov 2.

PMID:
27908222
26.

Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.

Dragoj M, Milosevic Z, Bankovic J, Tanic N, Pesic M, Stankovic T.

Cell Oncol (Dordr). 2017 Feb;40(1):47-62. doi: 10.1007/s13402-016-0304-6. Epub 2016 Nov 7.

PMID:
27822706
27.

NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.

Parry HM, Stevens T, Oldreive C, Zadran B, McSkeane T, Rudzki Z, Paneesha S, Chadwick C, Stankovic T, Pratt G, Zuo J, Moss P.

Oncotarget. 2016 Oct 18;7(42):68513-68526. doi: 10.18632/oncotarget.12097.

28.

A Hypomorphic PALB2 Allele Gives Rise to an Unusual Form of FA-N Associated with Lymphoid Tumour Development.

Byrd PJ, Stewart GS, Smith A, Eaton C, Taylor AJ, Guy C, Eringyte I, Fooks P, Last JI, Horsley R, Oliver AW, Janic D, Dokmanovic L, Stankovic T, Taylor AM.

PLoS Genet. 2016 Mar 18;12(3):e1005945. doi: 10.1371/journal.pgen.1005945. eCollection 2016 Mar.

29.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E.

Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.

30.

Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring.

Batinić B, Santrač A, Divović B, Timić T, Stanković T, Obradović ALj, Joksimović S, Savić MM.

Behav Brain Res. 2016 Feb 15;299:72-80. doi: 10.1016/j.bbr.2015.11.025. Epub 2015 Nov 24.

PMID:
26620494
31.

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P, Stankovic T.

Blood. 2016 Feb 4;127(5):582-95. doi: 10.1182/blood-2015-05-644872. Epub 2015 Nov 12.

PMID:
26563132
32.

New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.

Dinic J, Podolski-Renic A, Stankovic T, Bankovic J, Pesic M.

Curr Pharm Des. 2015;21(38):5589-604. Review.

PMID:
26429711
33.

T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.

Oldreive CE, Skowronska A, Davies NJ, Parry H, Agathanggelou A, Krysov S, Packham G, Rudzki Z, Cronin L, Vrzalikova K, Murray P, Odintsova E, Pratt G, Taylor AM, Moss P, Stankovic T.

Dis Model Mech. 2015 Nov;8(11):1401-12. doi: 10.1242/dmm.021147. Epub 2015 Aug 20.

34.

Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway.

Kwok M, Davies N, Agathanggelou A, Smith E, Petermann E, Yates E, Brown J, Lau A, Stankovic T.

Lancet. 2015 Feb 26;385 Suppl 1:S58. doi: 10.1016/S0140-6736(15)60373-7.

PMID:
26312880
35.

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Strefford JC, Kadalayil L, Forster J, Rose-Zerilli MJ, Parker A, Lin TT, Heppel N, Norris K, Gardiner A, Davies Z, Gonzalez de Castro D, Else M, Steele AJ, Parker H, Stankovic T, Pepper C, Fegan C, Baird D, Collins A, Catovsky D, Oscier DG.

Leukemia. 2015 Dec;29(12):2411-4. doi: 10.1038/leu.2015.217. Epub 2015 Aug 10. No abstract available.

36.

Biomechanical and Electromyographic Comparisons of Isometric Trunk Flexor Endurance Test Postures: Prone Plank Versus V-Sit.

Musalem LL, Stankovic T, Glisic D, Cook GE, Beach TA.

J Appl Biomech. 2015 Dec;31(6):469-75. doi: 10.1123/jab.2014-0197. Epub 2015 Aug 6.

PMID:
26252077
37.

Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.

te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N, Loden-van Straaten M, Navrkalova V, Trbusek M, Luijks DM, Zenz T, Skowronska A, Hoogendoorn M, Stankovic T, van Oers MH, Eldering E, Kater AP.

Cell Death Dis. 2015 Aug 6;6:e1852. doi: 10.1038/cddis.2015.223.

38.

Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives.

Stanković T, Dankó B, Martins A, Dragoj M, Stojković S, Isaković A, Wang HC, Wu YC, Hunyadi A, Pešić M.

Cancer Chemother Pharmacol. 2015 Sep;76(3):555-65. doi: 10.1007/s00280-015-2821-9. Epub 2015 Jul 22.

PMID:
26198315
39.

BOD1L Is Required to Suppress Deleterious Resection of Stressed Replication Forks.

Higgs MR, Reynolds JJ, Winczura A, Blackford AN, Borel V, Miller ES, Zlatanou A, Nieminuszczy J, Ryan EL, Davies NJ, Stankovic T, Boulton SJ, Niedzwiedz W, Stewart GS.

Mol Cell. 2015 Aug 6;59(3):462-77. doi: 10.1016/j.molcel.2015.06.007. Epub 2015 Jul 9.

40.

Chemo-protective and regenerative effects of diarylheptanoids from the bark of black alder (Alnus glutinosa) in human normal keratinocytes.

Dinić J, Ranđelović T, Stanković T, Dragoj M, Isaković A, Novaković M, Pešić M.

Fitoterapia. 2015 Sep;105:169-76. doi: 10.1016/j.fitote.2015.07.003. Epub 2015 Jul 7.

PMID:
26162555
41.

TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Mongini PK, Gupta R, Boyle E, Nieto J, Lee H, Stein J, Bandovic J, Stankovic T, Barrientos J, Kolitz JE, Allen SL, Rai K, Chu CC, Chiorazzi N.

J Immunol. 2015 Aug 1;195(3):901-23. doi: 10.4049/jimmunol.1403189. Epub 2015 Jul 1.

42.

Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion.

Timić Stamenić T, Joksimović S, Biawat P, Stanković T, Marković B, Cook JM, Savić MM.

J Psychopharmacol. 2015 Sep;29(9):1013-24. doi: 10.1177/0269881115590601. Epub 2015 Jun 23.

43.

Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.

Dragoj M, Milosevic Z, Bankovic J, Dinic J, Pesic M, Tanic N, Stankovic T.

Tumour Biol. 2015 Nov;36(11):8773-80. doi: 10.1007/s13277-015-3620-y. Epub 2015 Jun 9.

PMID:
26055143
44.

Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.

Stojković S, Podolski-Renić A, Dinić J, Stanković T, Banković J, Hadžić S, Paunović V, Isaković A, Tanić N, Pešić M.

Exp Cell Res. 2015 Jul 15;335(2):248-57. doi: 10.1016/j.yexcr.2015.05.018. Epub 2015 May 27.

PMID:
26026740
45.

USP7 is essential for maintaining Rad18 stability and DNA damage tolerance.

Zlatanou A, Sabbioneda S, Miller ES, Greenwalt A, Aggathanggelou A, Maurice MM, Lehmann AR, Stankovic T, Reverdy C, Colland F, Vaziri C, Stewart GS.

Oncogene. 2016 Feb 25;35(8):965-76. doi: 10.1038/onc.2015.149. Epub 2015 May 11.

PMID:
25961918
46.

Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.

Agathanggelou A, Weston VJ, Perry T, Davies NJ, Skowronska A, Payne DT, Fossey JS, Oldreive CE, Wei W, Pratt G, Parry H, Oscier D, Coles SJ, Hole PS, Darley RL, McMahon M, Hayes JD, Moss P, Stewart GS, Taylor AM, Stankovic T.

Haematologica. 2015 Aug;100(8):1076-85. doi: 10.3324/haematol.2014.115170. Epub 2015 Apr 3.

47.

Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.

Stojsic J, Stankovic T, Stojkovic S, Milinkovic V, Dinic J, Milosevic Z, Milovanovic Z, Tanic N, Bankovic J.

Exp Mol Pathol. 2015 Feb;98(1):27-32. doi: 10.1016/j.yexmp.2014.11.010. Epub 2014 Nov 20.

PMID:
25449334
48.

The impact of SF3B1 mutations in CLL on the DNA-damage response.

Te Raa GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MH, Kater AP, Eldering E.

Leukemia. 2015 May;29(5):1133-42. doi: 10.1038/leu.2014.318. Epub 2014 Nov 5.

PMID:
25371178
49.

The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53.

Thomas A, Perry T, Berhane S, Oldreive C, Zlatanou A, Williams LR, Weston VJ, Stankovic T, Kearns P, Pors K, Grand RJ, Stewart GS.

Oncogene. 2015 Jun;34(25):3336-48. doi: 10.1038/onc.2014.266. Epub 2014 Aug 18.

PMID:
25132271
50.

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.

Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, Dzodic R, Tanic N, Bankovic J.

Transl Res. 2014 Nov;164(5):411-23. doi: 10.1016/j.trsl.2014.06.005. Epub 2014 Jun 23.

PMID:
25016932

Supplemental Content

Loading ...
Support Center